Clinical trials
Resectable Non-small Cell Lung Cancer clinical trials
Below are recruiting resectable non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 354 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04780568RecruitingPhase 1
First-line osimertinib plus tegavivint for EGFR-mutant lung cancer
This Phase 1 study tests osimertinib combined with tegavivint as the first treatment for metastatic (stage IV) non-small cell lung cancer (NSCLC) with certain EGFR gene mutations. It aims to find the safest dose and see how well the combination can control cancer and side effects.
Columbus, OhioAges 18 years+ - NCT04853342RecruitingPhase 3
Furmonertinib after lung tumor removal for EGFR-mutated lung cancer
This trial tests whether furmonertinib, an oral targeted medicine, can improve outcomes after your lung tumor has been completely removed. It also checks for side effects and compares results against placebo in people with specific EGFR gene mutations.
Suzhou, JiangsuAges 18–75 - NCT04762459Enrolling by invitationPhase 3
Almonertinib after lung tumor surgery, with or without chemo
This study tests whether almonertinib taken after complete surgery can improve outcomes for people with stage II–IIIA non-small cell lung cancer (NSCLC) that has certain EGFR gene changes. It also compares almonertinib plus chemotherapy versus almonertinib alone to see which approach is safer and works better.
Beijing, Beijing MunicipalityAges 18–130 - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Scottsdale, ArizonaAges 18 years+ - NCT03546829RecruitingPhase 1
Testing targeted radiation plus short anti-microbial treatment
This early safety study tests a combination of focused radiation and a targeted anti-microbial (antibiotic/antifungal/antiviral/anti-parasite) plan for certain lung cancer that is starting to progress in a few spots. It aims to see whether this approach is safe and helps control the small areas of progressing cancer after prior treatment.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04410796RecruitingPhase 2
Osimertinib alone or with chemo for EGFR-mutant lung cancer
This trial tests whether osimertinib alone is as good as osimertinib plus chemotherapy for lung cancers that have a specific EGFR mutation. It may help by improving how well the cancer responds and slows growth in people with metastatic non-small cell lung cancer.
Sacramento, CaliforniaAges 18 years+ - NCT04267848RecruitingPhase 3
Testing immunotherapy with chemo after lung cancer surgery
This trial tests whether adding an immunotherapy medicine to standard chemotherapy after surgery can improve outcomes for some people with non-small cell lung cancer. It may help by boosting the immune system to reduce the chance the cancer comes back.
Anchorage, AlaskaAges 18 years+ - NCT04302025RecruitingPhase 2
Testing targeted and immunotherapy before lung cancer surgery
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
Duarte, CaliforniaAges 18 years+ - NCT04317534RecruitingPhase 2
Pembrolizumab after lung cancer surgery versus observation
This trial tests whether pembrolizumab (an immunotherapy drug) given after complete surgery can lower the chance that early-stage lung cancer comes back. You’ll be compared to standard follow-up without extra treatment to see if the drug helps more people stay cancer-free.
Tampa, FloridaAges 18 years+ - NCT04198766RecruitingPhase 1/Phase 2
New OX40 immunotherapy for advanced solid tumors
This trial tests a new immunotherapy drug (INBRX-106) alone or with Keytruda (pembrolizumab) for adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug can help the immune system fight cancer.
Duarte, CaliforniaAges 18 years+ - NCT03953144RecruitingPhase 1/Phase 2
3D lung surgery planning with a dye to find tumors
This trial tests a new way to plan and guide lung cancer surgery using a special dye that shows the tumor area during the operation. It may help surgeons remove the cancer more accurately while targeting only a small section of lung for certain early-stage patients.
Hamilton, OntarioAges 18 years+ - NCT03808337RecruitingPhase 2
SBRT radiation plus standard treatment for spread cancer
This trial looks at adding a focused radiation treatment called SBRT to standard care for cancers that have spread to a limited number of spots. It aims to control those spread-out tumors while still using the usual cancer treatment plan.
San Carlos, CaliforniaAges 18 years+ - NCT03412877RecruitingPhase 2
Personalized immune-cell therapy for advanced metastatic cancers
This trial tests a personalized cell therapy made from your own immune cells, changed to recognize “neoantigens” on cancer cells. It’s designed for people with metastatic (advanced spread) solid cancers or certain other cancers who have tried standard treatments but cancer is still growing.
Bethesda, MarylandAges 18–72 - NCT02468024RecruitingPhase 3
Surgery or focused radiation for early lung cancer
This study compares two treatments—removing only part of the lung (sublobar resection) versus a focused radiation approach (stereotactic ablative radiotherapy)—for early-stage non-small cell lung cancer. It aims to see which option works better with fewer problems for the right patients.
La Jolla, CaliforniaAges 18 years+ - NCT02570815RecruitingPhase 1
Fluorescent-guided robotic lung surgery for early lung cancer
This early-stage trial tests a robotic lung surgery that uses a special dye with near-infrared light to help the surgeon remove only the tumor area. If you have a small, early lung cancer, this approach may help improve accuracy while limiting how much lung is removed.
Hamilton, OntarioAges 18 years+ - NCT02133196RecruitingPhase 2
T-cell treatment for lung cancer that has spread
This Phase 2 study tests a T-cell–based immunotherapy for people with metastatic non-small cell lung cancer that has grown despite prior treatment. It may help your immune system recognize and fight your cancer using cells made from your tumor.
Bethesda, MarylandAges 18–72 - NCT01786590Recruiting
Ultrasound biopsy to stage lung cancer before SBRT
This trial looks at using a scope with an ultrasound tip (EBUS-TBNA) to take small tissue samples from lymph nodes to figure out the cancer stage before stereotactic body radiotherapy (SBRT). The goal is to help confirm how far the cancer has spread so SBRT can be planned appropriately.
Toronto, OntarioAges 18 years+ - NCT01803542RecruitingPhase 2
Stereotactic radiation for lung metastases or early lung tumors
This trial studies a precise, high-dose radiation technique (SBRT) to treat tumors in the lungs. It may help control cancer in people who either have early-stage lung cancer that is not fully operable or have limited lung metastases from other cancers.
Toronto, OntarioAges 18 years+ - NCT00897117Recruiting
Providing tumor tissue samples during lung cancer surgery
This study collects and analyzes tumor tissue from people with early-stage non-small cell lung cancer who are planning surgery. It may help researchers learn more about the cancer by studying samples taken at the time of your operation.
Nashville, TennesseeAges 18–120 - NCT00068003Enrolling by invitation
Harvesting Cancer Cells for Experimental Treatment
This trial collects immune cells from cancer patients or healthy volunteers to develop new experimental cancer treatments. Researchers will take a sample of your tumor or blood cells, grow them in the lab, and study how to use them to fight your cancer.
Bethesda, MarylandAges 18 years+ - NCT04459065RecruitingPhase 1/Phase 2
Imaging medicine to help find lung cancer during surgery
This trial tests a special imaging drug (IRDye800CW-nimotuzumab) that may help surgeons better see lung cancer tissue during planned lung surgery. Phase 1/2 looks mainly at safety and how well the imaging works to guide the operation.
Saskatoon, SaskatchewanAges 18–80 - NCT04209218Recruiting
Blood pressure and dexamethasone during lung cancer surgery
This study looks at how best to manage blood pressure during lung cancer surgery and whether giving dexamethasone (a steroid medicine) helps patients during the operation and recovery. You might benefit if you’re having longer lung cancer surgery and your heart and other organs are stable enough for the study.
Beijing, Beijing MunicipalityAges 50–90 - NCT07066813Recruiting
Lung cancer with air pockets: staging and treatment
This study looks at lung cancers that have air-filled spaces inside them. It explores how the stage of the cancer affects treatment outcomes. If you have this type of lung cancer and have had surgery, this trial may help doctors learn more about your condition.
Changsha, HunanAges Any age - NCT07820423Recruiting
AI tool predicts high-risk lung cancer linked to air-filled spaces
This study uses artificial intelligence to examine CT scans and predict whether lung cancer containing air-filled spaces is aggressive. It may help doctors tailor treatment after surgery.
Changsha, HunanAges 18 years+
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for resectable non-small cell lung cancer?
- Yes. Clin2 currently lists 354 recruiting resectable non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a resectable non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a resectable non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Squamous Cell Non-small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.